Amatuximab

Amatuximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	mesothelin
Clinical data
Other names	MORAb-009
ATC code	none;
Identifiers
CAS Number	931402-35-6 ;
ChemSpider	none;
UNII	6HP0354G04;
Chemical and physical data
Formula	C6394H9870N1694O2024S46
Molar mass	144331.89 g·mol−1
	(what is this?) (verify)

Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer.^[1] It was developed by Morphotek, Inc.

Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.^[2]^[3]

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab" (PDF). American Medical Association.
^ Baas HI, Hassan R, Nowak AK, Rice D (2018). "Chapter 53: Malignant mesothelioma.". In Pass HI, Ball D, Scagliotti GV (eds.). IASLC Thoracic Oncology (2nd ed.). Elsevier. pp. 536–549.e4. doi:10.1016/B978-0-323-52357-8.00053-6. ISBN 978-0-323-52357-8.
^ Baldo P, Cecco S (2017). "Amatuximab and novel agents targeting mesothelin for solid tumors". OncoTargets and Therapy. 10: 5337–5353. doi:10.2147/OTT.S145105. PMC 5687483. PMID 29184420.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab" (PDF). American Medical Association.

[2] Baas HI, Hassan R, Nowak AK, Rice D (2018). "Chapter 53: Malignant mesothelioma.". In Pass HI, Ball D, Scagliotti GV (eds.). IASLC Thoracic Oncology (2nd ed.). Elsevier. pp. 536–549.e4. doi:10.1016/B978-0-323-52357-8.00053-6. ISBN 978-0-323-52357-8.

[pmid29184420-3] Baldo P, Cecco S (2017). "Amatuximab and novel agents targeting mesothelin for solid tumors". OncoTargets and Therapy. 10: 5337–5353. doi:10.2147/OTT.S145105. PMC 5687483. PMID 29184420.

[1]

[2]

[3]